GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS inhibitor (KRASi), which was shown to sensitize pancreatic tumor cells to NK cell cytotoxicity The new data show that the combination promotes NK cell infiltration to provide superior disease control in orthotopic xenograft models, and provides novel mechanistic insight into KRAS-dependent anti-tumor NK regulation to establish a strong preclinical rationale for combining KRASi with GTB-5550 in pancreatic ductal adenocarcinoma (PDAC) A Phase 1a/1b basket trial with GTB-5550 monotherapy is currently underway (NCT07541573), which includes a cohort for PDAC patients, and the Company is considering potential options for a future Phase 1b study to evaluate the combination of GTB-5550 and a KRAS inhibitor SAN FRANCISCO, CALIFORNIA, Nov. 09, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, today announced preclinical data presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ. “We continue to make progress enrolling patients into our ongoing Phase 1a/1b dose escalation basket trial with GTB-5550 in multiple tumor types”, said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma has recently presented groundbreaking preclinical findings at the SITC 2026 Annual Meeting, held in Phoenix, Arizona. The research highlights the potential of GTB-5550, a tri-specific NK cell engager, in conjunction with a KRAS inhibitor to enhance anti-tumor activity against pancreatic ductal adenocarcinoma (PDAC).
- Combination therapy observed to sensitize pancreatic tumor cells.
- Significant NK cell infiltration results in superior disease control.
- New mechanistic insights into KRAS-dependent immune responses.
- Phase 1a/1b trial currently includes PDAC patients.
- Future studies planned to explore combination treatments.
GTBP continues to advance its clinical development, which is crucial in the fight against this challenging cancer type.
Why it matters: The insights from this presentation could shape future therapies and improve outcomes for patients with pancreatic cancer.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.